Jonathan H Soslow
Overview
Explore the profile of Jonathan H Soslow including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
91
Citations
981
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ostrominski J, Claggett B, Jerosch-Herold M, Raja A, Day S, Russell M, et al.
JAMA Cardiol
. 2025 Mar;
PMID: 40042824
Importance: Valsartan has been shown to attenuate phenotypic progression among individuals with early-stage sarcomeric hypertrophic cardiomyopathy (HCM). Myocardial tissue characterization by cardiac magnetic resonance (CMR) imaging may enhance mechanistic insights,...
2.
Killian M, Tamaroff J, Su K, Crum K, George-Durrett K, Markham L, et al.
Cardiol Young
. 2025 Feb;
:1-7.
PMID: 40012321
Background: Cardiomyopathy is the leading cause of death in patients with Duchenne muscular dystrophy. The relationship between cardiac and skeletal muscle progression is unclear. The objective of this study was...
3.
Esteso P, Auerbach S, Bansal N, Harris R, Soslow J, Birnbaum B, et al.
Cardiol Young
. 2025 Feb;
:1-6.
PMID: 40012319
Introduction: Duchenne muscular dystrophy is a devastating neuromuscular disorder characterized by the loss of dystrophin, inevitably leading to cardiomyopathy. Despite publications on prophylaxis and treatment with cardiac medications to mitigate...
4.
Kaufman B, Veerapandiyan A, Soslow J, Wittlieb-Weber C, Esteso P, Olson A, et al.
J Neuromuscul Dis
. 2025 Feb;
:22143602241303357.
PMID: 39973402
Background: A viral vector recombinant gene transfer therapy (GTT) has recently been approved by the FDA for males of all ages with Duchenne Muscular Dystrophy (DMD) without limitations regarding preexisting...
5.
Starnes J, Welch W, Henderson C, Hudson S, Risney S, Nicholson G, et al.
N Engl J Med
. 2025 Feb;
392(10):1033-1034.
PMID: 39938116
No abstract available.
6.
Starnes J, Weiner J, George-Durrett K, Crum K, Henderson C, Campbell M, et al.
Circ Cardiovasc Imaging
. 2024 Dec;
17(12):e017287.
PMID: 39629588
Background: Cardiomyopathy is the leading cause of death in boys with Duchenne muscular dystrophy (DMD). While cardiac magnetic resonance (CMR) is routinely used to assess fibrosis and left ventricular (LV)...
7.
Jain S, Anderson S, Steele J, Wilson H, Muniz J, Soslow J, et al.
EClinicalMedicine
. 2024 Sep;
76:102809.
PMID: 39290640
Background: We aimed to study the clinical characteristics, myocardial injury, and longitudinal outcomes of COVID-19 vaccine-associated myocarditis (C-VAM). Methods: In this longitudinal retrospective observational cohort multicenter study across 38 hospitals...
8.
Jacobs H, Soslow J, Cornicelli M, Merves S, Garg R, Patel M, et al.
J Cardiovasc Magn Reson
. 2024 Sep;
26(2):101091.
PMID: 39270799
Background: Cardiovascular magnetic resonance (CMR) is used to diagnose myocarditis in adults and children based on the original Lake Louise criteria (LLC) and more recently the revised LLC. The major...
9.
Ireland C, Burstein D, Day S, Raja A, Russell M, Zahka K, et al.
Circ Heart Fail
. 2024 Aug;
17(8):e011663.
PMID: 39087355
Background: The health-related quality of life (HRQOL) and cardiopulmonary exercise testing (CPET) performance of individuals with subclinical and early stage hypertrophic cardiomyopathy (HCM) have not been systematically studied. Improved understanding...
10.
Lubarsky D, Clark D, Crum K, Karpinos A, Austin E, Soslow J
Pulm Circ
. 2024 Jul;
14(3):e12413.
PMID: 39022309
Post-acute sequelae of Coronavirus (PASC), or Long COVID, has emerged as a critical health concern. The clinical manifestations of PASC have been described, but studies have not quantified the cardiopulmonary...